The HypoFocal-SBRT trial will therefore investigate a new and accurately staged patient cohort, leading clinical PCa trials into the era of PSMA-PET/CT and challenging comparability with former trials. The gene discussed is FOLH1; the disease is posterior cortical atrophy.